MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12879-024-09891-z

Медицинская библиотека · BMC infectious diseases · 2024

Longevity of hybrid immunity against SARS-CoV-2 in adults vaccinated with an adenovirus-based COVID-19 vaccine.

Mvula Memory, Mtonga Fatima, Mandolo Jonathan, Jowati Chisomo, Kalirani Alice, Chigamba Precious, Lisimba Edwin, Mitole Ndaona, Chibwana Marah G, Jambo Kondwani C

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Hybrid immunity provides better protection against COVID-19 than vaccination or prior natural infection alone. It induces high magnitude and broadly cross-reactive neutralising anti-Spike IgG antibodies. However, it is not clear how long these potent antibodies last, especially in the context of adenovirus-based COVID-19 vaccines.

METHODS

We conducted a longitudinal cohort study and enrolled 20 adults who had received an adenovirus-based COVID-19 vaccine before a laboratory-confirmed SARS-CoV-2 infection. We followed up the study participants for 390 days post the initial breakthrough infection. We assessed the longevity and cross-reactive breadth of serum antibodies against SARS-CoV-2 variants of concern (VOCs), including Omicron.

RESULTS

The binding anti-Spike IgG antibodies remained within the reported putative levels for at least 360 days and were cross-neutralising against Beta, Gamma, Delta, and Omicron. During the follow up period, a median of one SARS-CoV-2 re-infection event was observed across the cohort, but none resulted in severe COVID-19. Moreover, the re-exposure events were associated with augmented anti-Spike and anti-RBD IgG antibody titres.

CONCLUSIONS

This study confirms that hybrid immunity provides durable broadly cross-reactive antibody immunity against SARS-CoV-2 variants of concern for at least a year (360 days), and that it is further augment by SARS-CoV-2 re-exposure.

Для цитирования: Mvula Memory, Mtonga Fatima, Mandolo Jonathan, Jowati Chisomo, Kalirani Alice, Chigamba Precious, Lisimba Edwin, Mitole Ndaona, Chibwana Marah G, Jambo Kondwani C. Longevity of hybrid immunity against SARS-CoV-2 in adults vaccinated with an adenovirus-based COVID-19 vaccine.. BMC infectious diseases. 2024. DOI: 10.1186/s12879-024-09891-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.